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ABSTRACT
Background. Waiting time from diagnosis to treatment
has emerged as an important quality indicator in cancer
care. This study was designed to determine the impact of
waiting time on long-term outcome of patients with eso-
phageal cancer who are treated with neoadjuvant therapy
followed by surgery or primary surgery.
Methods. Patients who underwent esophagectomy for
esophageal cancer at the University Medical Center
Utrecht between 2003 and 2014 were included. Patients
treated with neoadjuvant therapy followed by surgery and
treated with primary surgery were separately analyzed. The
influence of waiting time on survival was analyzed using
Cox proportional hazard analyses. Kaplan–Meier curves
for short (\8 weeks) and long (C8 weeks) waiting times
were constructed.
Results. A total of 351 patients were included; 214
received neoadjuvant treatment, and 137 underwent pri-
mary surgery. In the neoadjuvant group, the waiting time
had no impact on disease-free survival (DFS) [hazard ratio
(HR) 0.96, 95 % confidence interval (CI) 0.88–1.04;
p = 0.312] or overall survival (OS) (HR 0.96, 95 % CI
0.88–1.05; p = 0.372). Accordingly, no differences were
found between neoadjuvantly treated patients with waiting
times of \8 and C8 weeks in terms of DFS (p = 0.506)
and OS (p = 0.693). In the primary surgery group, the
waiting time had no impact on DFS (HR 1.03, 95 % CI
0.95–1.12; p = 0.443) or OS (HR 1.06, 95 % CI 0.99–
1.13; p = 0.108). Waiting times of \8 weeks versus
C8 weeks did not result in differences regarding DFS
(p = 0.884) or OS (p = 0.374).
Conclusions. In esophageal cancer patients treated with
curative intent by either neoadjuvant therapy followed by
surgery or primary surgery, waiting time from diagnosis to
treatment has no impact on long-term outcome.
Esophageal cancer is the eighth most common cancer
and the sixth most common cause of cancer-related mor-
tality worldwide.1,2 Surgical resection is the cornerstone of
curative treatment with a 5-year survival rate of 34–36 %
in patients treated with primary surgery.2 Multimodality
treatment with neoadjuvant chemoradiotherapy or periop-
erative chemotherapy is increasingly applied and results in
improved 5-year survival rates of 36–47 %.3–6
Waiting times have been shown to be an important
quality indicator for cancer care.7 In the Netherlands, the
period between diagnosis and treatment is currently rec-
ommended to be reduced to a maximum of 5 weeks, and
all Dutch hospitals have been obliged to publish their
waiting times once per month and submit these to the
Dutch Healthcare authority.8,9 Waiting time before treat-
ment is distressing for patients and impairs their quality of
life.10–12 Several studies investigated the length of waiting
time in esophageal cancer.13–18 However, these studies
lacked survival analyses, are currently outdated, or only
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included patients treated with primary surgery.13–18 There-
fore, literature about the impact of waiting time on the long-
term outcome in patients with esophageal cancer is scarce.
This study was designed to determine the impact of
waiting time from diagnosis to treatment on disease-free
survival (DFS) and overall survival (OS) in patients with
esophageal cancer undergoing esophagectomy with cura-
tive intent, either with or without neoadjuvant therapy.
MATERIALS AND METHODS
Study Population
Data regarding 426 consecutive patients who were
planned for esophagectomy with curative intent for eso-
phageal cancer at the University Medical Center Utrecht
(UMC Utrecht), from October 2003 to December 2014,
were extracted from a prospectively collected database.
Exclusion criteria consisted of emergency esophagec-
tomies, participation in the Barrett’s esophagus
surveillance program, detected unresectable tumor (cT4b)
or metastatic disease (M1) intraoperatively, and in-hospital
or 90-day postoperative mortality. Institutional review
board approval was obtained, and the informed consent
requirement was waived for this study.
Pretreatment Workup
A substantial proportion of the patients were referred to
the UMC Utrecht for treatment after their esophageal
cancer diagnosis was established in a referring hospital.
The remaining patients had the UMC Utrecht as their first-
line hospital and were directly referred by a general prac-
titioner (GP). In all patients, upper gastrointestinal
endoscopy with biopsy was performed to confirm the
diagnosis of esophageal cancer. Further investigations
included endoscopic ultrasound (EUS), computed tomog-
raphy (CT) scanning of thorax and abdomen, and
ultrasonography of the neck. F-fluorodeoxyglucose posi-
tron emission tomography (FDG-PET) was not regularly
used but has become part of the standard staging in our
center since July 2013. All patients were discussed at a
multidisciplinary tumor board in which a definitive treat-
ment plan was constructed.
Treatment
According to the Dutch guidelines, patients with locally
advanced disease (cT C 2 or cN?) received either periop-
erative chemotherapy or neoadjuvant chemoradiotherapy.3,4
Before June 2012, the standard treatment for patients with
esophageal cancer in our center consisted of perioperative
chemotherapy.3,6 From June 2012, patients received
neoadjuvant chemoradiotherapy.4 Before 2008, neoadjuvant
therapy was not part of the standard protocol and most
patients were operated on without neoadjuvant therapy. In
addition, primary surgical esophageal resection was per-
formed in patients who were not eligible for neoadjuvant
treatment. After esophagectomy with en bloc lym-
phadenectomy, all patients underwent gastric tube
reconstruction with a cervical anastomosis. All patients were
divided into one of two groups, including a group of patients
who received neoadjuvant treatment followed by surgery,
and a group of patients who underwent primary surgery.
Follow-Up
Clinical and histopathological characteristics were
retrieved from the database. The resected specimens were
reviewed by pathologists in accordance with the 7th edition
of the American Joint Committee on Cancer TNM staging
system.19 A radical resection (R0) was defined using the
College of American Pathologist criteria.20 Following
hospital discharge, patients were followed at the outpatient
clinic for 5 years. In case of clinical suspicion of tumor
recurrence, diagnostic imaging was performed. For patients
who were discharged after 5 years of follow-up, the gen-
eral practitioner was contacted for additional information
on recurrent disease. DFS was defined as the number of
months from the start date of neoadjuvant therapy until the
date of recurrent disease in the neoadjuvant group and from
the date of surgery until the date of recurrent disease in the
primary surgery group. OS was defined as the number of
months from the start date of neoadjuvant therapy until the
date of death or last follow-up in the neoadjuvant group
and from the date of surgery until the date of death or last
follow-up in the primary surgery group.
Statistical Analysis
The distribution of continuous characteristics was
reported as median [interquartile range (IQR)] or
mean ± standard deviation (SD), and categorical variables
were reported as numbers and percentages. For the
neoadjuvantly treated group, waiting time was defined as
the number of weeks from the date of diagnosis to the start
date of neoadjuvant therapy. For the primary surgery
group, waiting time was defined as the number of weeks
from the date of diagnosis to the date of surgery. The date
of the first upper gastrointestinal endoscopy, on which the
diagnosis of esophageal cancer had been established by
histology from biopsies, was used as date of diagnosis.
Spearman’s rank correlation coefficients (q) were cal-
culated to determine whether waiting time from diagnosis
to treatment was influenced by (i.e., correlated with) the
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baseline characteristics. Spearman’s q was interpreted as
follows: a positive or negative correlation coefficient of
0.80–1.00 was considered very strong; 0.60–0.79, strong;
0.40–0.59, moderate; 0.20–0.39, weak; and 0–0.20, very
weak.
The prognostic influence of the studied parameters,
including waiting time and all baseline characteristics of
DFS and OS, was assessed using univariable Cox propor-
tional hazard analysis, which provided hazard ratios (HRs)
along with 95 % confidence intervals (CIs). Studied
parameters that yielded a p value \0.10 in univariable
analysis were entered in multivariable Cox proportional
hazards models, separately for DFS and OS. The original
scale of waiting time was used for Cox regression analysis,
because logarithmic transformation did not improve the
proportional hazard assumption.
In accordance with literature and based on guidelines,
waiting time was initially categorized into three groups:\5,
5–8, andC8 weeks.9,18 However, due to a limited number of
patients, the number of groups was reduced to two groups
with representative sample sizes, consisting of short and long
time waiters (\8 and C8 weeks), respectively. Both groups
were compared using the log-rank test after construction of
Kaplan–Meier survival curves. All statistical analyses were
performed using IBM SPSS Statistics Version 21 for Win-




Of the 426 patients who were planned for esophagectomy
in the study period, 59 were excluded because of emergency
esophagectomy (n = 3), participation in the Barrett’s
esophagus surveillance program (n = 7), detected unre-
sectable tumor (cT4b) or metastatic disease (M1)
intraoperatively (n = 21), and in-hospital or 90-day post-
operative mortality (n = 29). In 15 patients, waiting time
could not be calculated, because the date of diagnosis or the
starting date of neoadjuvant therapy was unknown. The
remaining 351 patients were included in this study (Table 1).
The number of patients in the neoadjuvant group was
214. Mean age at diagnosis was 63 years ± 8.4 (SD). The
majority of patients was male (n = 171, 80 %), received
neoadjuvant chemoradiotherapy (n = 111, 52 %), under-
went transthoracic esophagectomy (n = 176, 82 %), and
was pathologically staged as ypT3-4a (n = 111, 51 %),
ypN0 (n = 108, 51 %), and R0 (n = 198, 93 %). The
primary surgery group consisted of 137 patients. Mean age
at diagnosis was 64 years ± 9.9 (SD). The majority of
patients was male (n = 93, 68 %), underwent transthoracic
esophagectomy (n = 84, 61 %), and was pathologically
staged as pT3-4a (n = 96, 70 %), pN? (n = 91, 66 %),
and R0 (n = 117, 85 %).
Waiting Time and Baseline Characteristics
The median time from diagnosis to neoadjuvant treat-
ment was 6.4 weeks (IQR 5.3–7.7) for patients in the
neoadjuvant group. Spearman’s rank correlation coeffi-
cients showed weak to very weak correlations of waiting
time with all baseline characteristics ranging from -0.22 to
?0.16 (Table 2). In the primary surgery group, patients had
a median time from diagnosis to surgery of 9.7 weeks (IQR
8.0–13.1). Spearman’s rank correlation coefficients showed
weak to very weak correlations of waiting time with
baseline characteristics ranging from -0.22 to ?0.25
(Table 2). The median waiting time of excluded patients
detected with an unresectable tumor (cT4b) or metastatic
disease (M1) intraoperatively (n = 21) was 6.1 weeks
(IQR 4.7–11.0) in the neoadjuvant group (n = 7) and
8.8 weeks (IQR 4.2–12.4) in the primary surgery group
(n = 14).
Waiting Time and Survival
For surviving patients in the neoadjuvant group, the
median follow-up was 28 months (range 7–75). Of the 214
patients, 102 (48 %) developed recurrent disease during
follow-up. Median DFS was 16 months (range 3–75),
whereas median OS was 19 months (range 5–77). The OS
rates at 1 and 3 years were 84 and 48 %, respectively.
Univariable analyses of all studied variables in relation to
DFS and OS are presented in Appendix Table 5. Waiting
time did not influence significantly the DFS (HR 0.96,
95 % CI 0.88–1.04; p = 0.312) or OS (HR 0.96, 95 % CI
0.88–1.05; p = 0.372; Table 3). For DFS, multivariable
analysis identified ypT3-4a stage, ypN? stage, and irradi-
cality as independent and significant prognostic factors
associated with worse DFS. For OS, ypN? stage remained
independently and significantly associated with worse OS
in multivariable analysis. In addition, a stratified analysis
for type of neoadjuvant therapy showed that waiting time
did not influence OS significantly in patients treated with
chemotherapy (HR 0.92, 95 % CI 0.81–1.03; p = 0.159) or
in patients treated with chemoradiotherapy (HR 1.05, 95 %
CI 0.90–1.23; p = 0.509).
For surviving patients in the primary surgery group, the
median follow-up was 56 months (range 10–135). During
follow-up, 67 of 137 patients (49 %) developed recurrent
disease. Median DFS in the primary surgery group was
18 months (range 2–133), whereas median OS was
23 months (range 2–135). The OS rates at 1, 3, and 5 years
were 80, 50, and 45 %, respectively. Univariable analyses
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TABLE 1 Baseline characteristics of 351 patients treated with neoadjuvant therapy followed by esophagectomy or primary surgery for
esophageal cancer
Neoadjuvant therapy
total (n = 214) n (%)*
Primary surgery total
(n = 137) n (%)*
Age at diagnosis, year [mean ± SD] 63 (8.4) 64 (9.9)
Gender
Male 171 (80) 93 (68)
Female 43 (20) 44 (32)
ASA score
1 49 (23) 35 (26)
2 136 (64) 70 (51)
C3 29 (14) 32 (23)
Tumor location
Upper esophagus 3 (1) 0 (0)
Middle esophagus 30 (14) 29 (21)
Distal esophagus 105 (49) 62 (45)
Gastroesophageal junction 76 (36) 46 (34)
Neoadjuvant therapy
None 0 (0) 137 (100)
Chemotherapy 103 (48) 0 (0)
Chemoradiotherapy 111 (52) 0 (0)
Surgical approach
Transthoracic 176 (82) 84 (61)
Transhiatal 38 (18) 53 (39)
Histological type
Adenocarcinoma 175 (82) 92 (67)
Squamous cell carcinoma 39 (18) 44 (32)
Other 0 (0) 1 (1)
pT stage
T0 39 (18) 2 (2)
T1-2 64 (30) 39 (28)
T3-4a 111 (51) 96 (70)
pN stage
N0 108 (51) 46 (34)
N1 54 (25) 39 (29)
N2-3 52 (24) 52 (38)
Radicality
R0 198 (93) 117 (85)
R1 16 (8) 20 (15)
Referral
By general practitioner 23 (11) 34 (25)
By another hospital 191 (89) 103 (75)
Year of diagnosis
2003–2005 2 (1) 34 (25)
2006–2008 22 (10) 50 (36)
2009–2011 91 (43) 33 (24)
2012–2014 99 (46) 20 (15)
SD standard deviation, ASA American Society of Anesthesiologists
* Percentages may not add up to 100 due to rounding
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of all studied variables in relation to DFS and OS are
presented in Appendix Table 6. Waiting time from diag-
nosis to surgery did not influence significantly DFS (HR
1.03, 95 % CI 0.95–1.12; p = 0.443) or OS (HR 1.06,
95 % CI 0.99–1.13; p = 0.108; Table 4). For DFS, mul-
tivariable analysis identified pT3-4a stage and pN? stage
as independent and significant prognostic factors associated
with worse DFS. For OS, pN? stage and irradicality
remained independently and significantly associated with
worse OS in multivariable analysis.
Impact of Short versus Long Waiting Time on Long-
term Survival
In the neoadjuvant group, no significant differences
were found between patients with short (\8 weeks,
n = 165) and long (C8 weeks, n = 49) waiting times
regarding DFS (p = 0.506) and OS (p = 0.693; Figs. 1a,
b). In addition, in the primary surgery group, short
(n = 37) and long (n = 100) waiting times did not result in
significant differences in terms of DFS (p = 0.884) or OS
(p = 0.374; Figs. 1c, d).
DISCUSSION
This single-center cohort study investigated the influ-
ence of waiting time on long-term outcome in patients who
underwent esophagectomy with curative intent for eso-
phageal cancer, either treated with neoadjuvant therapy or
treated with primary surgery. This study showed that
waiting time did not significantly impact long-term out-
come for both patient groups.
This is the first study to demonstrate that waiting time
does not significantly affect long-term outcome regarding
DFS and OS for patients treated with neoadjuvant therapy
followed by surgery for esophageal cancer. In line with
previous studies, waiting time did not impact DFS or OS in
patients treated with primary surgery.17,18 The majority of
the included patients were treated within a time frame of
approximately 3 months. Therefore, the findings of this
study reflect the fact that if patients are treated within a
clinically relevant waiting period, early treatment does not
improve survival.
Because multimodality treatment was introduced
recently as the standard of care, the median follow-up
duration of 28 months is relatively short in the neoadjuvant
group. However, median time to recurrence is 9 months
and the majority of patients develop recurrent disease
within 2 years after surgery.21,22 Therefore, the follow-up
duration of the neoadjuvant group in this study was con-
sidered sufficient to assess accurately the impact of waiting
time on both DFS and OS.
To provide more insight into the influence of waiting
time on long-term outcome, waiting time was initially
categorized into three groups in this study according to
Grotenhuis et al.18 Due to a limited number of patients,
two rather than three groups, consisting of patients with
short (\8 weeks) and long (C8 weeks) waiting times,
were composed. This cutoff was used to create two
groups with representative sample sizes. The results
showed no difference in survival regarding DFS and OS
for patients with waiting times of \8 weeks from diag-
nosis to the start of neoadjuvant therapy. In addition, for
patients treated with primary surgery, no differences were
found between short and long waiting times on long-term
outcome.
In this study, waiting time was not influenced by one or
more baseline characteristics. All correlations were weak to
very weak (Spearman’s rank correlation coefficient\0.4).
This finding suggests that a longer waiting time did not
result in worse tumor characteristics with more advanced
disease or in a smaller rate of radical tumor resections.
Patients with shorter and longer waiting times had com-
parable pTN stages and R0 resections. For patients treated
with neoadjuvant therapy, the waiting time did not differ
between the type of neoadjuvant therapy (neoadjuvant
chemoradiotherapy or perioperative chemotherapy).
In other types of cancer, several studies reported mixed
findings about the potential association between waiting
time and long-term survival. For breast cancer, studies
mainly reported better outcomes with shorter waiting time,
whereas in lung cancer, mixed findings of positive, nega-
tive, and no associations were reported.23–27 For pancreatic
TABLE 2 Spearman’s rank correlation coefficients (q) for waiting
time for patients treated with neoadjuvant therapy followed by
esophagectomy or primary surgery for esophageal cancer
Neoadjuvant therapy Primary surgery
Age at diagnosis 0.11 0.25
Gender 0.02 0.03
ASA score 0.16 0.14
Tumor location 0.05 -0.03
Type of neoadjuvant therapy -0.08 n.a.
Surgical approach 0.02 0.22
Histological type 0.01 0.01
pT stage 0.06 -0.22
pN stage 0.07 -0.11
Radicality 0.01 0.09
Referral 0.16 0.10
Year of diagnosis -0.22 0.17
ASA American Society of Anesthesiologists, n.a. not applicable
Positive or negative coefficients indicate positive or negative corre-
lations with 1 or -1 being the strongest positive or negative
relationship
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and colorectal cancer, most studies reported no associations
between waiting time and survival.28–31
Numerous reports showed that increased waiting time
results in major psychosocial stress in cancer patients.
Patients prefer to be treated as soon as possible for the
fear of tumor progression.32–34 Until hard conclusions
can be drawn on the effect of waiting time on patients’
prognosis, efforts should be made to keep waiting time
to a minimum. In the current study, the median waiting
time between diagnosis and neoadjuvant treatment was
6.4 weeks, whereas in patients treated with primary
surgery it was 9.7 weeks. The waiting time reflects
resource availability and efficiency, which indicates that
there is still room for improvement.35 However, the main
reason for the long waiting time should be sought,
because we are a tertiary referral center. To reduce
waiting time, a more efficient diagnostic workup for
patients with suspected esophageal cancer was recently
introduced in our hospital, including rapid diagnostic
pathways and frequent multidisciplinary team meetings
for the establishment of a definitive treatment plan for
each individual patient.36 This diagnostic workup resul-
ted in a reduced median waiting time of 6.1 weeks for
the neoadjuvant group and 8.1 weeks for the primary
surgery group during the period of 2012–2014 (data not
shown). Further steps still need to be taken to reduce the
waiting time from the determination of the treatment
plan until the start of treatment. The waiting time of the
primary surgery group in this study is likely caused by
the complexity of esophageal surgery planning.
Esophagectomies are highly complex procedures with a
median surgery duration of 6 h for transthoracic resec-
tion and therefore put a lot of pressure on operating
room schedules.37
TABLE 3 Univariable and multivariable analysis of influence of waiting time on disease-free survival and overall survival in patients treated
with neoadjuvant therapy followed by esophagectomy for esophageal cancer
Univariable analysis Multivariable analysis
HR 95 % CI p value HR 95 % CI p value
Disease-free survival
Additional week waiting time 0.96 0.88–1.05 0.362 0.96 0.88–1.04 0.312
ypT stage
T0 Reference – – Reference
T1-2 1.55 0.69–3.47 0.288 1.22 0.54–2.79 0.635
T3-4a 3.94 1.89–8.25 \0.001 2.40 1.10–5.22 0.028
ypN stage
N0 Reference – – Reference – –
N1 1.83 1.11–3.03 0.019 1.72 1.03–2.88 0.039
N2-3 4.42 2.77–7.03 \0.001 3.09 1.81–5.25 \0.001
Radicality
R0 Reference – – Reference – –
R1 4.41 2.46–7.91 \0.001 1.93 1.00–3.70 0.049
Overall survival
Additional week waiting time 1.00 0.91–1.08 0.910 0.96 0.88–1.05 0.372
ypT stage
T0 Reference – – Reference – –
T1-2 0.95 0.45–2.02 0.895 0.71 0.33–1.54 0.385
T3-4a 2.54 1.31–4.94 0.006 1.46 0.71–3.00 0.300
ypN stage
N0 Reference – – Reference – –
N1 2.07 1.25–3.43 0.005 2.04 1.21–3.43 0.007
N2-3 4.15 2.57–6.69 \0.001 3.04 1.74–5.33 \0.001
Radicality
R0 Reference – – Reference – –
R1 4.40 2.46–7.87 \0.001 1.90 0.99–3.66 0.055
HR hazard ratio, CI confidence interval
Analysis was performed using Cox regression model. Bold values indicate statistically significant results (e.g., p\ 0.05). Only waiting time and
variables with p\ 0.1 from univariable analysis are reported and were used for multivariable analysis
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In our center, patients do not undergo standard disease
evaluation after initial diagnosis of esophageal cancer until
esophagectomy, and therefore possible tumor progression
could only be detected during surgery. The median waiting
time of 21 excluded patients detected with an unre-
sectable tumor (cT4b) or metastatic disease (M1)
intraoperatively and was comparable with the included
patients who underwent esophagectomy with curative
intent. Therefore, no significant selection bias of these
patients is expected.
Of note, this study contains information about in-hos-
pital waiting time only. Because patient waiting time (i.e.,
TABLE 4 Univariable and multivariable analysis of influence of waiting time on disease-free survival and overall survival in patients treated
with primary surgery for esophageal cancer
Univariable analysis Multivariable analysis
HR 95 % CI p value HR 95 % CI p value
Disease-free survival
Additional week waiting time 0.97 0.91 0.222 1.03 0.95 0.443
ASA score
1 Reference – – Reference – –
2 0.63 0.37–1.09 0.100 0.95 0.53–1.72 0.876
C3 0.54 0.27–1.07 0.075 0.95 0.32–1.39 0.284
Surgical approach
Transthoracic Reference – – Reference – –
Transhiatal 0.50 0.29–0.86 0.012 0.66 0.36–1.22 0.182
pT stage
T0-2 Reference – – Reference – –
T3-4a 4.08 2.02–8.26 \0.001 2.51 1.13–5.57 0.024
pN stage
N0 Reference – – Reference – –
N1 2.89 1.35–6.20 0.006 2.25 1.00–5.05 0.029
N2-3 5.20 2.58–10.50 \0.001 2.92 1.33–6.45 0.008
Radicality
R0 Reference – – Reference – –
R1 2.95 1.67–5.21 \0.001 1081 0.97–3.37 0.063
Additional year date diagnosis 0.88 0.81–0.97 0.009 0.94 0.85–1.05 0.266
Overall survival
Additional week waiting time 0.99 0.95–1.05 0.803 1.06 0.99–1.13 0.108
Tumor location
Middle esophagus Reference – – Reference – –
Distal esophagus 0.68 0.37–1.24 0.211 0.54 0.28–1.03 0.060
Gastro-esophageal junction 1.74 0.96–3.15 0.067 1.12 0.60–2.09 0.728
pT stage
T0-2 Reference – – Reference – –
T3-4a 2.95 1.62–5.38 \0.001 1.86 0.92–3.78 0.086
pN stage
N0 Reference – – Reference – –
N1 2.89 1.52–5.49 0.001 2.76 1.40–5.45 0.004
N2-3 3.25 1.78–5.94 \0.001 2.37 1.16–4.84 0.018
Radicality
R0 Reference – – Reference – –
R1 2.65 1.56–4.51 \0.001 2.08 1.17–3.70 0.013
Additional year date diagnosis 0.92 0.84–1.01 0.070 0.97 0.88–1.08 0.584
Analysis was performed using Cox regression model. Bold values indicate statistically significant results (e.g., p\ 0.05). Only waiting time and
variables with p\ 0.1 from univariable analysis are reported and were used for multivariable analysis
ASA American Society of Anesthesiologists, HR hazard ratio, CI confidence interval
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time between onset of symptoms and presentation to the
GP) and doctor waiting time (i.e., time between presenta-
tion to the GP and endoscopy) account for a larger part of
the total waiting time, these periods may still have an
influence on long-term outcome.13,15,18 It would be inter-
esting to identify what time frame is appropriate and
whether a delay of any length does negatively influence
long-term oncologic outcomes. Unfortunately, this study
was not designed for such analysis.
In conclusion, this is the first study to demonstrate that
waiting time does not impact long-term outcome in patients
treated with neoadjuvant therapy combined with surgical
resection for curable esophageal cancer. Furthermore, a
longer waiting time did not affect the oncologic outcome
for patients treated with primary surgery.
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FIG. 1 The influence of short (\8 weeks) and long (C8 weeks)
waiting time on disease-free survival (a, c) and overall survival (b, d)
in patients treated with neoadjuvant therapy followed by surgery (a,
b), and patients treated with primary surgery (c, d) for esophageal
cancer. Survival curves were plotted by the Kaplan–Meier method
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TABLE 5 Univariable analysis of influence of waiting time on disease-free survival and overall survival in patients treated with neoadjuvant
therapy followed by esophagectomy for esophageal cancer
Disease-free survival Overall survival
HR 95 % CI p value HR 95 % CI p value
Univariable analysis
Additional week waiting time 0.96 0.88–1.05 0.362 1.00 0.91–1.08 0.910
Age at diagnosis 1.01 0.91–1.13 0.805 1.01 0.98–1.03 0.503
Gender
Female Reference – – Reference – –
Male 1.28 0.77–2.13 0.342 1.01 0.62–1.65 0.962
ASA classification
1 Reference – – Reference – –
2 0.84 0.52–1.33 0.452 0.389
[3 1.33 0.72–2.47 0.366 0.81 – 0.480
Tumor location
Upper esophagus Reference – – Reference – –
Middle esophagus 0.59 0.12–3.06 0.534 0.61 0.13–2.83 0.524
Distal esophagus 0.87 0.19–3.95 0.853 0.74 0.18–3.05 0.677
Gastroesophageal junction 0.70 0.15–3.24 0.647 0.53 0.13–2.23 0.389
Neoadjuvant therapy
Chemotherapy Reference – – Reference – –
Chemoradiotherapy 0.90 0.60–1.34 0.594 0.96 0.63–1.46 0.849
Surgical approach
Transthoracic Reference – – Reference – –
Transhiatal 0.75 0.44–1.26 0.272 0.72 0.43–1.22 0.226
Histological type
Adenocarcinoma Reference – – Reference – –
Squamous cell carcinoma 0.87 0.49–1.53 0.621 1.45 0.85–2.45 0.172
pT stage
T0 Reference – – Reference – –
T1-2 1.55 0.69–3.47 0.288 0.95 0.45–2.02 0.895
T3-4a 3.94 1.89–8.25 \0.001 2.54 1.31–4.94 0.006
pN stage
N0 Reference – – Reference – –
N1 1.83 1.11–3.03 0.019 2.07 1.25–3.43 0.005
N2-3 4.42 2.77–7.03 \0.001 4.15 2.57–6.69 \0.001
Radicality
R0 Reference – – Reference – –
R1 4.41 2.46–7.91 \0.001 4.40 2.46–7.87 \0.001
Referral
By general practitioner Reference – – Reference – –
By another hospital 0.94 0.52–1.72 0.847 0.93 0.53–1.78 0.928
Additional year date diagnosis 1.01 0.91–1.13 0.805 1.07 0.95–1.21 0.250
Analysis was performed using Cox regression model
ASA American Society of Anesthesiologists, HR hazard ratio, CI confidence interval
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